The estimated Net Worth of Lee F Md Ph D Allen is at least $94.5 Tisíc dollars as of 30 September 2019. Lee Allen owns over 978 units of Spectrum Pharmaceuticals stock worth over $9,924 and over the last 17 years Lee sold SPPI stock worth over $84,617.
Lee has made over 10 trades of the Spectrum Pharmaceuticals stock since 2009, according to the Form 4 filled with the SEC. Most recently Lee sold 978 units of SPPI stock worth $27,384 on 30 September 2019.
The largest trade Lee's ever made was buying 3,500 units of Spectrum Pharmaceuticals stock on 5 July 2017 worth over $59,500. On average, Lee trades about 307 units every 102 days since 2007. As of 30 September 2019 Lee still owns at least 9,635 units of Spectrum Pharmaceuticals stock.
You can see the complete history of Lee Allen stock trades at the bottom of the page.
Lee's mailing address filed with the SEC is C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM, NC, 27707.
Over the last 21 years, insiders at Spectrum Pharmaceuticals have traded over $34,101,027 worth of Spectrum Pharmaceuticals stock and bought 60,000 units worth $132,000 . The most active insiders traders include Rajesh C Md Shrotriya, Raymond W Cohen a Thomas J Riga. On average, Spectrum Pharmaceuticals executives and independent directors trade stock every 26 days with the average trade being worth of $68,584. The most recent stock trade was executed by Nora Brennan on 26 May 2023, trading 32,387 units of SPPI stock currently worth $35,626.
spectrum's core mission is to bring pharmaceutical products to patients for unmet medical needs. to this mission, we bring our years of drug development expertise, coupled with the insight of working in many different oncology indications. spectrum and its subsidiaries have six marketed oncology/hematology products, three for different types of non-hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia (all) and one for multiple myeloma. there are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.
Spectrum Pharmaceuticals executives and other stock owners filed with the SEC include: